India can supply 5 billion Covaxin dosages to world post WHO nod: PM Modi

Published On 2021-11-01 07:40 GMT   |   Update On 2021-11-01 10:09 GMT
Advertisement

New Delhi: Terming it as Indias contribution to reduce vaccine inequity, Prime Minister Narendra Modi said if the WHO approved Covaxin, Indias indigenous vaccine, India can produce five billion dosages to supply to the developing countries as its contribution to reducing vaccine inequities.

Modi was speaking at the first session on 'Global Economy and Global Health' at the inaugural ceremony of the G20 Leaders' Summit with the other leaders at Rome in Italy. In his intervention, the Prime Minister highlighted India's contribution in the fight against the pandemic.

Advertisement

He mentioned medical supplies to more than 150 countries.

"The Prime Minister conveyed that India has not only vaccinated more than a billion of our citizens but more importantly, we are ready to produce more than five billion vaccine dosage by the end of 2022 and this would be available for not only our citizens but also for the rest of the world. And that, this is our own contribution to reducing vaccine inequities, especially in the developing world," Foreign Secretary Harsh Vardhan Shringla said, adding, "We also believe that the WHO's approval for emergency use authorisation for Covaxin pending with them, would facilitate this process of assisting other countries."

Shringla briefed the media on the second day of Modi's Italy visit for the G20 Leaders' Summit.

Modi spoke about India's vision of 'One Earth One Health', which is essentially the need for a collaborative approach in the international domain in the fight against Covid-19 pandemic, Shringla said, adding, "Collaboration in R&D to collaborations in combating pandemics, collaborations across the board in developing mechanisms that can cope with future pandemics and future global health issues."

There was an emphasis on vaccine research, manufacturing and innovation. "We have invested a fair amount in that effort in order to make it available for our citizens and citizens all across the world."

Modi stressed on the need for resilient global supply chains and also mentioned India's bold economic reforms and lowering of the cost of doing business in India. He spoke about innovations in India and efforts at developing a culture of innovations. He invited the G20 countries to make India their partner in economic recovery and supply chain diversification.

The Prime Minister brought out the fact that despite the challenges of the pandemic, India continued to be a trusted partner in the context of reliable supply chains, the IT sector, the BPOs, we did not allow the pandemic to come in the way of our contribution in the overall chain in the global processes.

"Modi expressed satisfaction over G20's decision to come up with the 15 per cent minimum corporate tax. It was at the 2014 G20 Summit that the Prime Minister had first proposed this idea of a minimum corporate tax in order to prevent to some extent the evasion of taxes.

"Today there is satisfaction over the fact that the G20 has actually adopted this. This has become a global norm. And this is a very important step in ensuring more rationalised global tax structures and better cooperation in the international domain when it comes to issues like tax evasion, money laundering, corruption, among others, some of the issues that G20 is currently dealing with," the Indian Foreign Secretary said.

Earlier at the G20 Summit venue, PM Modi and other global leaders first interacted informally with each other, posed for a family photo and generally exchanged pleasantries. Modi held two bilateral meetings with the French President Emmanuel Macron and the Singapore Prime Minister Lee Hsien Loong.

Prior to the G20 Summit, Modi had met Pope Francis at the Vatican and attended the cultural event and the dinner after it.

Read also: Covishield re-vaccination after Covaxin: SC saids to wait for WHO decision

Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News